Innovair is not intended for the initial management of asthma. The dosage of the components of Innovair is individual and should be adjusted to the severity of the disease. This should be considered not only when treatment with combination products is initiated but also when the dose is adjusted. If an individual patient should require a combination of doses other than those available in the combination inhaler, appropriate doses of β2-agonists and/or corticosteroids by individual inhalers should be prescribed.
Beclometasone dipropionate in Innovair is characterised by an extrafine particle size distribution which results in a more potent effect than formulations of beclometasone dipropionate with a non-extrafine particle size distribution (beclometasone dipropionate 100 mcg extrafine in Innovair are equivalent to beclometasone dipropionate 250 mcg in a nonextrafine formulation). Therefore, the total daily dose of beclometasone dipropionate administered in Innovair should be lower than the total daily dose of beclometasone dipropionate administered in a non-extrafine beclometasone dipropionate formulation.
This should be taken into consideration when a patient is transferred from beclometasone dipropionate non-extrafine formulations to Innovair; the dose of beclometasone dipropionate should be lower and will need to be adjusted to the individual needs of patients.
Adult ≥18 years: One or 2 inhalations twice daily. The maximum daily dose is 4 inhalations daily.
Patients should be regularly reassessed by a physician, so that the dosage of Innovair remains optimal and is only changed on medical advice. The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. When control of symptoms is maintained with the lowest recommended dosage, then the next step could include a test of inhaled corticosteroid alone.
Patients should be advised to take Innovair everyday even when asymptomatic.
Special Patient Groups: There is no need to adjust the dose in elderly patients. There are no data available for use of Innovair in patients with hepatic or renal impairment.
Administration: Innovair is for inhalation use.
To ensure proper administration of the drug, the patient should be shown how to use the inhaler correctly by a physician or other health professional. Correct use of the pressurised metered dose inhaler is essential in order that treatment is successful. The patient should be advised to read the Patient Information Leaflet carefully and follow the instructions for use.
Before using the inhaler for the 1st time or if the patient have not used the inhaler for ≥14 days, release 1 puff into the air to make sure the inhaler is working properly. Whenever possible, stand or sit in an upright position when inhaling.